Tumor-associated macrophages provide significant prognostic information in urothelial bladder cancer

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Boström, Minna M ^a   Irjala, Heikki ^a,b   Mirtti, Tuomas ^c   Taimen, Pekka ^b   Kauko, Tommi ^d   Ålgars, Annika ^a,b   Jalkanen, Sirpa ^a   Boström, Peter J ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD68 ANTIGEN; CLEVER 1 PROTEIN; MAC387 PROTEIN; STABILIN 1 PROTEIN; UNCLASSIFIED DRUG; BCG VACCINE; CALGRANULIN B; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; HOMING RECEPTOR; LEUKOCYTE ANTIGEN; NERVE CELL ADHESION MOLECULE; STAB1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER RISK; CD68+ MACROPHAGE; CLEVER 1+ MACROPHAGE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAC387+ MACROPHAGE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; STABILIN 1+ MACROPHAGE; TRANSURETHRAL RESECTION; TUMOR ASSOCIATED LEUKOCYTE; UNIVARIATE ANALYSIS; UROTHELIAL BLADDER CANCER; CHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; URINARY BLADDER NEOPLASMS; UROTHELIUM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BCG VACCINE; CALGRANULIN B; CELL ADHESION MOLECULES, NEURONAL; COHORT STUDIES; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, LYMPHOCYTE HOMING; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84941284478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133552     Document Type: Article

References (30)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144(5):646-74. doi:10.1016/j.cell.2011.02.013 PMID: 21376230.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203): 436-44. doi:10.1038/nature07205 PMID: 18650914.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917):860-7. doi:10.1038/nature01322 PMID: 12490959; PubMed Central PMCID: PMCPMC2803035.
4. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008; 222:155-61. doi:10.1111/j.1600-065X.2008.00607.x PMID: 18364000.
5. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010; 22(2):231-7. doi:10.1016/j.coi.2010.01.009 PMID: 20144856.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. doi:10.3322/caac.20107 PMID: 21296855.
7. Sauter G, Algaba F, et al. MAe. Tumours of the urinary system: non-invasive urothelial neoplasias. In: JN E, G S, Jl E, I S, editors. WHO classification of classification of tumours of the urinary system and male genital organs. Lyon: IARCC Press; 2004. p. 29-34.
8. Sobin LH, Gospodariwicz MK, Christian Wittekind E. TNM classification of malignant tumors. UICC International Union Against Cancer. In: Sobin L, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors UICC International Union Against Cancer. 7 ed. Est Sussex, UK: Wiley- Blackwell; 2009 p. 262-5.
9. Palani S, Maksimow M, Miiluniemi M, Auvinen K, Jalkanen S, Salmi M. Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages. Eur J Immunol. 2011; 41(7):2052-63. doi:10.1002/eji.201041376 PMID: 21480214.
10. Irjala H, Elima K, Johansson EL, Merinen M, Kontula K, Alanen K, et al. The same endothelial receptor controls lymphocyte traffic both in vascular and lymphatic vessels. Eur J Immunol. 2003; 33(3):815-24. doi:10.1002/eji.200323859 PMID: 12616502.
11. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science. 1992; 257(5075):1407-9. PMID: 1529341.
12. Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundström J, Salmi M, et al. Type and location of tumorinfiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer. 2012; 131(4):864-73. doi:10.1002/ijc.26457 PMID: 21952788.
13. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumorassociated macrophages in solid tumor: A meta-analysis of the literature. PLoS One. 2012; 7(12): e50946. doi:10.1371/journal.pone.0050946 PMID: 23284651; PubMed Central PMCID: PMCPMC3532403.
14. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000; 7(7):263-9. PMID: 10910229.
15. Sjödahl G, Lövgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, et al. Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscleinvasive tumors. Urol Oncol. 2014; 32(6):791-7. doi:10.1016/j.urolonc.2014.02.007 PMID: 24794251.
16. Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol. 2009; 181(4):1894-900.: doi:10.1016/j.juro.2008.11.090 PMID: 19237175.
17. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol. 2009; 55(6):1386-95. doi:10.1016/j.eururo.2009.01.040 PMID: 19193487.
18. Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L. Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now? Adv Urol. 2012; 2012:232609. doi:10.1155/2012/232609 PMID: 22919375; PubMed Central PMCID: PMCPMC3420223.
19. Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS. The role of neutrophils and TNF-related apoptosis- inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev. 2009; 28(3-4):345-53. doi:10.1007/s10555-009-9195-6PMID: 19967427.
20. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics. 2003; 21(18):1315-30. PMID: 14750899.
21. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. doi:10.1038/nature13904 PMID: 25428503.
22. Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, et al. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol. 2012; 19(12):3979-86. doi:10.1245/s10434-012-2415-2PMID: 22622474.
23. Shabo I, Stål O, Olsson H, Doré S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 2008; 123(4):780-6. doi:10.1002/ijc.23527 PMID: 18506688.
24. Subimerb C, Pinlaor S, Khuntikeo N, Leelayuwat C, Morris A, McGrath MS, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol Med Rep. 2010; 3(4):597-605. doi:10.3892/mmr-00000303 PMID: 21472285.
25. Lopez-Beltran A, Requena MJ, Alvarez-Kindelan J, Quintero A, Blanca A, Montironi R. Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. J Clin Pathol. 2007; 60(3):332-5. doi:10.1136/jcp.2006.038802 PMID: 16882698; PubMed Central PMCID: PMCPMC1860555.
26. Tungekar MF, Heryet A, Gatter KC. The L1 antigen and squamous metaplasia in the bladder. Histopathology. 1991; 19(3):245-50. PMID: 1717359.
27. Soulas C, Conerly C, Kim WK, Burdo TH, Alvarez X, Lackner AA, et al. Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation. Am J Pathol. 2011; 178(5):2121-35. doi:10.1016/j.ajpath.2011.01.023 PMID: 21514427; PubMed Central PMCID: PMCPMC3081227.
28. Goebeler M, Roth J, Teigelkamp S, Sorg C. The monoclonal antibody MAC387 detects an epitope on the calcium-binding protein MRP14. J Leukoc Biol. 1994; 55(2):259-61. PMID: 7507970.
29. Adachi H, Tsujimoto M. FEEL-1, a novel scavenger receptor with in vitro bacteria-binding and angiogenesis- modulating activities. J Biol Chem. 2002; 277(37):34264-70. doi:10.1074/jbc.M204277200 PMID: 12077138.
30. Kzhyshkowska J. Multifunctional receptor stabilin-1 in homeostasis and disease. Scientific World Journal. 2010; 10:2039-53. doi:10.1100/tsw.2010.189PMID: 20953554.